Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
December 01 2016 - 4:05PM
- Positions Intellia for R&D growth and progress toward
clinical studies -- Accommodates hiring plans to support pipeline
of CRISPR/Cas9 based therapeutics -
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced the move to
its new laboratory facilities at 40 Erie Street, in Cambridge. In
recognition of Intellia’s leadership in genome editing, Intellia
CEO and Founder Nessan Bermingham, Ph.D., President and CEO of the
Massachusetts Life Sciences Center Travis McCready, and President
and CEO of MassBio Bob Coughlin, will inaugurate the new facility
today at an evening ribbon cutting ceremony.
“The field of genome editing is rapidly evolving and our work to
develop therapies for patients requires that we have the
infrastructure necessary for R&D growth and prepare for
preclinical studies and clinical trials,” said Nessan Bermingham,
Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics.
“To reach our goals, we continue to recruit top talent and ensure
our quality workforce has the appropriate facilities and tools
necessary to translate CRISPR/Cas9 into life-transforming
products.”
“This new facility allows Intellia to further advance our
scientific programs and to continue to leverage our Massachusetts
location alongside leading biotech research and academic
institutions,” Dr. Bermingham added.
About Intellia’s New HeadquartersThe new
Intellia headquarters was specifically designed to accommodate the
Company’s growing R&D, operations teams and administrative
staff. Additionally, Intellia will maintain operations at its
current facility at 130 Brookline Street in Cambridge. The new
facility will increase Intellia’s total laboratory and office space
from the current 15,000 sq. ft. to more than 80,000 sq. ft. and
will allow the company to double its team to more than 200
employees.
“Intellia Therapeutics’ new headquarters is a testament to the
potential of the company and the promise their transformative gene
therapy represents to patients and their families living with
severe and life-threatening diseases,” said Governor Charlie
Baker. “The innovations coming out of Massachusetts have a
dramatic impact across the global life sciences sector, and we look
forward to Intellia Therapeutics’ continued growth and
contributions to this field.”
“We are thrilled to celebrate Intellia Therapeutics’ growth as a
great example of the opportunity available to companies in the
Massachusetts life sciences ecosystem,” said Travis McCready,
President & CEO of the Massachusetts Life Sciences Center. “The
genomics space is exciting, carrying enormous potential for saving
lives and improving patient care. Companies like Intellia have
provided a strong blueprint for success to other genomics startups
in Massachusetts.”
“We are excited to celebrate with Intellia Therapeutics as they
take this significant step to expand into new headquarters,” said
Robert K. Coughlin, President & CEO of MassBio. “We are proud
to have Intellia as part of the Massachusetts life sciences
community and look forward to their successes as they advance the
use of cutting-edge genome editing to develop treatments and cures
for patients around the world.”
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on the
development of proprietary, potentially curative therapeutics using
the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. Our combination of deep scientific, technical and
clinical development experience, along with our leading
intellectual property portfolio, puts us in a unique position to
unlock broad therapeutic applications of the CRISPR/Cas9 technology
and create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us
on Twitter @intelliatweets.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Any
forward-looking statements in this press release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. For a
discussion of risks and uncertainties, and other important factors,
any of which could cause our actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent quarterly report on Form
10-Q filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and
Exchange Commission. All information in this press release is
as of the date of the release, and Intellia Therapeutics undertakes
no duty to update this information unless required by law.
Intellia Contacts:
Media:Jennifer Mound SmoterChief External Affairs
& Communications Officer+1
857-706-1071jenn.smoter@intelliatx.com |
|
Investors:John GrazianoTrout Group+ 1
646-378-2942jgraziano@troutgroup.com Chad RubinTrout Group+
1 646-378-2947crubin@troutgroup.com |
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024